Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling

There has been great recent interest in the medical and statistical literature in the assessment and validation of surrogate endpoints as proxies for clinical endpoints in medical studies. More recently, authors have focused on using metaanalytical methods for quantification of surrogacy. In this article, we extend existing procedures for analysis based on the accelerated failure time model to this setting. An advantage of this approach relative to proportional hazards model is that it allows for analysis in the semicompeting risks setting, where we model the region where the surrogate endpoint occurs before the true endpoint. Several estimation methods and attendant inferential procedures are presented. In addition, between- and within-trial methods for evaluating surrogacy are developed; a novel principal components procedure is developed for quantifying trial-level surrogacy. The methods are illustrated by application to data from several studies in colorectal cancer.

[1]  F. Grémy,et al.  Adjuvant immunotherapy with nonviable mycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients , 1984, Cancer.

[2]  J. Neyman,et al.  A simple stochastic model of recovery, relapse, death and loss of patients. , 1951, Human biology.

[3]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Debashis Ghosh,et al.  Semiparametric inferences for association with semi‐competing risks data , 2006, Statistics in medicine.

[5]  J O'Quigley,et al.  A two-stage procedure for survival studies with surrogate endpoints. , 1995, Biometrics.

[6]  N. Nagelkerke,et al.  A note on a general definition of the coefficient of determination , 1991 .

[7]  Bing Li,et al.  A deviance function for the quasi-likelihood method , 1993 .

[8]  L Nyström,et al.  Statistical Analysis , 2008, Encyclopedia of Social Network Analysis and Mining.

[9]  Jinfeng Xu,et al.  Statistical Analysis of Illness–Death Processes and Semicompeting Risks Data , 2010, Biometrics.

[10]  I. James,et al.  Linear regression with censored data , 1979 .

[11]  Y. Li,et al.  Predicting treatment effects using biomarker data in a meta‐analysis of clinical trials , 2010, Statistics in medicine.

[12]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[13]  J O'Quigley,et al.  Estimating average regression effect under non-proportional hazards. , 2000, Biostatistics.

[14]  Zhiliang Ying,et al.  Survival analysis with median regression models , 1995 .

[15]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[16]  D. Oakes.  A Model for Association in Bivariate Survival Data , 1982 .

[17]  G. Guyatt,et al.  Validity of composite end points in clinical trials , 2005, BMJ : British Medical Journal.

[18]  Mark J. van der Laan,et al.  Estimation of Causal Effects of Community Based Interventions , 2010 .

[19]  Michael R Elliott,et al.  A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials , 2010, Biometrics.

[20]  Zhiliang Ying,et al.  A Large Sample Study of Rank Estimation for Censored Regression Data , 1993 .

[21]  Jason P. Fine,et al.  On semi-competing risks data , 2001 .

[22]  M. Pagano,et al.  Survival analysis. , 1996, Nutrition.

[23]  Richard J. Cook,et al.  Some comments on efficiency gains from auxiliary information for right-censored data , 2001 .

[24]  D. Oakes,et al.  Bivariate survival models induced by frailties , 1989 .

[25]  T. Louis,et al.  Inferences on the association parameter in copula models for bivariate survival data. , 1995, Biometrics.

[26]  H. Malani,et al.  A modification of the redistribution to the right algorithm using disease markers , 1995 .

[27]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[28]  C. Begg,et al.  On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) , 2000 .

[29]  D.,et al.  Regression Models and Life-Tables , 2022 .

[30]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[31]  Martin T. Wells,et al.  Model Selection and Semiparametric Inference for Bivariate Failure-Time Data , 2000 .

[32]  Debashis Ghosh,et al.  On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm , 2009, Biometrics.

[33]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[34]  John O'Quigley,et al.  Proportional Hazards Regression , 2008 .

[35]  Gerard J. van den Berg,et al.  The nonparametric identification of treatment effects in duration models , 2003 .

[36]  Vance W Berger,et al.  Does the Prentice criterion validate surrogate endpoints? , 2004, Statistics in medicine.

[37]  Donglin Zeng,et al.  Efficient resampling methods for nonsmooth estimating functions. , 2008, Biostatistics.

[38]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[39]  P Flandre,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1999, Statistics in Medicine.

[40]  Jim Q. Smith,et al.  Evaluating Causal effects using Chain Event Graphs , 2006, Probabilistic Graphical Models.

[41]  D. Clayton.  A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .

[42]  Raymond Fitzgerald.  Improving the Information Content of Sonar Signals , 1997 .

[43]  James M. Robins,et al.  Comparing two failure time distributions in the presence of dependent censoring , 1996 .

[44]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[45]  Donald B. Rubin,et al.  Estimation of Causal Effects via Principal Stratification When Some Outcomes are Truncated by “Death” , 2003 .

[46]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[47]  Thomas A. Louis,et al.  Nonparametric analysis of an accelerated failure time model , 1981 .

[48]  Michael E. Tipping,et al.  Probabilistic Principal Component Analysis , 1999 .

[49]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[50]  Peter B. Gilbert,et al.  Evaluating Causal Effect Predictiveness of Candidate Surrogate Endpoints , 2006 .

[51]  Debashis Ghosh,et al.  Links between analysis of surrogate endpoints and endogeneity , 2010, Statistics in medicine.

[52]  R. Nelsen.  An Introduction to Copulas , 1998 .

[53]  Jeremy M G Taylor,et al.  A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker , 2002, Biometrics.

[54]  D. Oakes,et al.  Semiparametric inference in a model for association in bivanate survival data , 1986 .

[55]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[56]  Debashis Ghosh,et al.  Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data , 2008, Biometrics.